Landogrozumab

This article will address the issue of Landogrozumab, which is of utmost importance and relevance today. Landogrozumab has been the subject of debate and analysis in different areas, since its influence impacts various aspects of daily life. Throughout history, Landogrozumab has been a source of interest for researchers, specialists and enthusiasts, who have dedicated time and effort to understand its meaning and scope. In this sense, this article aims to explore the multiple facets and dimensions that surround Landogrozumab, offering a broad and balanced vision that allows the reader to delve into its complexity and relevance today.

Landogrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
Other namesLY2495655
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6338H9790N1694O1988S42
Molar mass142874.43 g·mol−1

Landogrozumab (INN; development code LY2495655) is a humanized monoclonal antibody and experimental pharmaceutical drug designed for the treatment of muscle wasting disorders.

The drug was developed by Eli Lilly and Company.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Wikious
Boobota
Sagapedia